325 related articles for article (PubMed ID: 32132245)
1. The Bewildering Antitubercular Action of Pyrazinamide.
Lamont EA; Dillon NA; Baughn AD
Microbiol Mol Biol Rev; 2020 May; 84(2):. PubMed ID: 32132245
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
[TBL] [Abstract][Full Text] [Related]
3. Impact of the host environment on the antitubercular action of pyrazinamide.
Lamont EA; Baughn AD
EBioMedicine; 2019 Nov; 49():374-380. PubMed ID: 31669220
[TBL] [Abstract][Full Text] [Related]
4. Characterization of pyrazinamide resistance in consecutive multidrug-resistant
Mansjo M; Werngren J; Hoffner S
Int J Mycobacteriol; 2017; 6(2):156-161. PubMed ID: 28559517
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
Che Y; Bo D; Lin X; Chen T; He T; Lin Y
BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
[TBL] [Abstract][Full Text] [Related]
6. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
Sengstake S; Bergval IL; Schuitema AR; de Beer JL; Phelan J; de Zwaan R; Clark TG; van Soolingen D; Anthony RM
BMC Infect Dis; 2017 Jul; 17(1):491. PubMed ID: 28697808
[TBL] [Abstract][Full Text] [Related]
7. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
8. Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of
Tam KK; Leung KS; Siu GK; Chang KC; Wong SS; Ho PL; Leung EK; Yam WC
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31189582
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.
Liu W; Chen J; Shen Y; Jin J; Wu J; Sun F; Wu Y; Xie L; Zhang Y; Zhang W
Clin Microbiol Infect; 2018 Sep; 24(9):1016.e1-1016.e5. PubMed ID: 29288021
[TBL] [Abstract][Full Text] [Related]
10. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
Sun F; Li Y; Chen Y; Guan W; Jiang X; Wang X; Ren P; Li J; Shi J; He G; Wu M; Tang P; Wang F; Sheng Y; Huang F; Zhou Z; Huang H; Hong L; Liu Q; Zhang Y; Zhang W
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578402
[TBL] [Abstract][Full Text] [Related]
11. Global status of phenotypic pyrazinamide resistance in
Wang Z; Tang Z; Heidari H; Molaeipour L; Ghanavati R; Kazemian H; Koohsar F; Kouhsari E
J Chemother; 2023 Nov; 35(7):583-595. PubMed ID: 37211822
[TBL] [Abstract][Full Text] [Related]
12. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan.
Kuhlin J; Smith C; Khaemraev A; Tigay Z; Parpieva N; Tillyashaykhov M; Achar J; Hajek J; Greig J; du Cros P; Moore D
Int J Tuberc Lung Dis; 2018 May; 22(5):544-550. PubMed ID: 29663960
[TBL] [Abstract][Full Text] [Related]
13. Non-
Werngren J; Alm E; Mansjö M
J Clin Microbiol; 2017 Jun; 55(6):1920-1927. PubMed ID: 28404681
[TBL] [Abstract][Full Text] [Related]
14. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Bwalya P; Yamaguchi T; Mulundu G; Nakajima C; Mbulo G; Solo ES; Fukushima Y; Kasakwa K; Suzuki Y
Tuberculosis (Edinb); 2018 Mar; 109():117-122. PubMed ID: 29559115
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran.
Doustdar F; Khosravi AD; Farnia P
Microb Drug Resist; 2009 Dec; 15(4):251-6. PubMed ID: 19857130
[TBL] [Abstract][Full Text] [Related]
16. pncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects.
Wu X; Lu W; Shao Y; Song H; Li G; Li Y; Zhu L; Chen C
Infect Genet Evol; 2019 Aug; 72():147-150. PubMed ID: 30447296
[TBL] [Abstract][Full Text] [Related]
17. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
Rosen BC; Dillon NA; Peterson ND; Minato Y; Baughn AD
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855077
[TBL] [Abstract][Full Text] [Related]
18. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations.
Gu Y; Yu X; Jiang G; Wang X; Ma Y; Li Y; Huang H
Diagn Microbiol Infect Dis; 2016 Mar; 84(3):207-11. PubMed ID: 26775806
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance in Mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness.
Miotto P; Cirillo DM; Migliori GB
Chest; 2015 Apr; 147(4):1135-1143. PubMed ID: 25846529
[TBL] [Abstract][Full Text] [Related]
20. Introducing RpsA Point Mutations Δ438A and D123A into the Chromosome of Mycobacterium tuberculosis Confirms Their Role in Causing Resistance to Pyrazinamide.
Shi W; Cui P; Niu H; Zhang S; Tønjum T; Zhu B; Zhang Y
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30858213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
